Memantine Hydrochloride for Subdural Hematoma
(TASD Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a medication called Memantine to help elderly patients recover better after brain surgery. The goal is to improve recovery and reduce neurological problems. Memantine has been used to treat Alzheimer's disease and other neurological disorders.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but you cannot participate if you are using NMDA antagonists or acetylcholinesterase inhibitors. If you are on these medications, you would need to stop them to join the trial.
Is memantine hydrochloride safe for humans?
How does the drug memantine hydrochloride differ from other treatments for subdural hematoma?
Memantine hydrochloride is unique because it is an excitatory amino acid (EAA) antagonist that has been used for neurodegenerative diseases like Alzheimer's, but it is now being explored for subdural hematoma to prevent brain damage from reduced blood flow. Unlike standard treatments that focus on surgical removal of the hematoma, memantine targets the chemical processes in the brain to protect it from further injury.26789
Eligibility Criteria
This trial is for adults aged 18-100 who've had surgery for chronic subdural hematoma and experienced spreading depolarization within 48 hours post-operation. They must have an electrode strip placed during surgery. It's not for those with severe liver or kidney issues, known allergies to memantine, current memantine users, women not using dual contraception, or patients needing large craniotomy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Surgery and Initial Monitoring
Subjects undergo surgery for chronic or subacute subdural hematoma and are monitored for spreading depolarizations and seizures using a recording electrode placed during surgery.
Treatment
Subjects with detected spreading depolarization are randomized to receive either memantine or placebo for 7 days.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of neurological deficits and adverse events.
Treatment Details
Interventions
- Memantine Hydrochloride
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of New Mexico
Lead Sponsor